Acadia Pharmaceuticals (ACAD) Total Non-Current Liabilities (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted Total Non-Current Liabilities of $421.0 million for Q2 2026, up 22.19% on a QoQ basis from $344.5 million in Q1 2026, and up 12.37% year-over-year from $374.6 million in Q2 2025.
Powered by 
Analysis
Acadia Pharmaceuticals (ACAD) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals has reported Total Non-Current Liabilities for 16 years, with the latest figure at $421.0 million in Q2 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 12.37% year-over-year to $421.0 million in Q2 2026; TTM through Jun 2026 was $421.0 million, a 12.37% increase from a year earlier, with the FY2025 full-year figure at $317.7 million, down 27.29% from the prior year.
- Total Non-Current Liabilities was $421.0 million for Q2 2026 at Acadia Pharmaceuticals, up from $344.5 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $436.9 million in Q4 2024, with the low at $170.3 million in Q3 2022.
- Average Total Non-Current Liabilities over 5 years is $307.5 million, with a median of $331.1 million recorded in 2025.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities jumped 69.38% in 2023, then slipped 27.29% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $178.3 million in 2022, then surged by 69.38% to $302.1 million in 2023, then jumped by 44.65% to $436.9 million in 2024, then retreated by 27.29% to $317.7 million in 2025, then jumped by 32.52% to $421.0 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $421.0 million (Q2 2026), $344.5 million (Q1 2026), and $317.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.01 Bn | 628.25 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 468.55 Bn | 462.03 Bn | 12.70 Bn | 106.45 Bn |
| 3 | Merck | 365.49 Bn | 358.40 Bn | 12.21 Bn | 16.16 Bn |
| 4 | Novartis Ag | 272.39 Bn | 265.10 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Astrazeneca | 253.18 Bn | 247.96 Bn | 12.86 Bn | -967.00 Mn |
| 6 | Amgen | 219.53 Bn | 205.54 Bn | 7.24 Bn | 81.11 Bn |
| 7 | Gilead Sciences | 187.85 Bn | 184.59 Bn | 6.22 Bn | 36.04 Bn |
| 8 | Pfizer | 160.56 Bn | 149.16 Bn | 10.94 Bn | 100.86 Bn |
| 9 | Vertex Pharmaceuticals | 130.81 Bn | 122.96 Bn | 2.84 Bn | 5.92 Bn |
| 10 | Acadia Pharmaceuticals | 4.38 Bn | 3.42 Bn | 279.64 Mn | 420.98 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 420.98 Mn |
| Mar 31, 2026 | 344.53 Mn |
| Dec 31, 2025 | 317.67 Mn |
| Sep 30, 2025 | 399.61 Mn |
| Jun 30, 2025 | 374.63 Mn |
| Mar 31, 2025 | 347.16 Mn |
| Dec 31, 2024 | 436.91 Mn |
| Sep 30, 2024 | 384.37 Mn |
| Jun 30, 2024 | 385.04 Mn |
| Mar 31, 2024 | 379.79 Mn |
| Dec 31, 2023 | 302.05 Mn |
| Sep 30, 2023 | 257.71 Mn |
| Jun 30, 2023 | 237.72 Mn |
| Mar 31, 2023 | 250.22 Mn |
| Dec 31, 2022 | 178.33 Mn |
| Sep 30, 2022 | 170.34 Mn |
| Jun 30, 2022 | 172.37 Mn |
| Mar 31, 2022 | 175.08 Mn |
| Dec 31, 2021 | 152.19 Mn |
| Sep 30, 2021 | 145.90 Mn |
API Access
Acadia Pharmaceuticals Total Non-Current Liabilities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=ACAD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "total-non-current-liabilities", "ticker": "ACAD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=ACAD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();